Related Experiment Video
Updated: Jul 1, 2026
06:12
Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl4) Exposure Through an Orogastric Tube
Published on: April 28, 2020
Flucloxacillin-induced liver injury
1Institute of Cellular Medicine, Newcastle University Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, UK. E.A.G.Andrews@ncl.ac.uk
Toxicology
|September 17, 2008
Summary
Flucloxacillin frequently causes drug-induced liver injury (DILI) in Europe. This review explores flucloxacillin
Area of Science:
- Pharmacology and Toxicology
- Hepatology
- Genetics
Background:
- Flucloxacillin is a significant cause of drug-induced liver injury (DILI) in Europe, with an incidence of approximately 8.5 per 100,000 new users.
- The precise mechanism underlying flucloxacillin-induced hepatotoxicity remains unknown.
- Current understanding suggests that both genetic predisposition and environmental factors contribute to the development of DILI.
Purpose of the Study:
- To review the current knowledge regarding the disposition of flucloxacillin within the liver.
- To investigate potential mechanisms through which flucloxacillin may induce liver injury.
- To identify candidate genes that may influence an individual's susceptibility to flucloxacillin-induced liver injury.
Main Methods:
- Literature review of existing studies on flucloxacillin.
- Analysis of pharmacokinetic and pharmacodynamic data related to flucloxacillin in hepatic tissue.
- Exploration of genetic association studies and candidate gene approaches for DILI.
Main Results:
- Summarizes current understanding of flucloxacillin's metabolic fate and distribution in the liver.
- Discusses proposed mechanisms of flucloxacillin-induced liver injury, including immune-mediated and direct toxic effects.
- Highlights potential genetic variations associated with altered flucloxacillin metabolism or immune response.
Conclusions:
- Flucloxacillin-induced liver injury is a complex condition influenced by drug disposition and host factors.
- Further research into genetic susceptibility is crucial for predicting and preventing DILI.
- Understanding these factors will aid in personalized medicine approaches for flucloxacillin therapy.
Related Concept Videos
01:28Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...